Debbie Robbrecht retweeted
Welcome you all to the sunny ☀️ and really hot Madrid!!! Lovely discussion about #bladdercancer Very happy to have you all here!!! @amerseburger @dralvaropinto @APoprach @laconss @fcala4 @DebbieRobbrecht
Het landelijk platform CUPP-NL is officieel in de lucht! #primairetumoronbekend #CUP cupp-nl.eu Laten we de handen ineen slaan! iknl.nl/nieuws/2021/landelij…
Outcomes of treatment choices in poor prognosis prostate cancer: not a... sciencedirect.com/science/ar…
Debbie Robbrecht retweeted
Today, three of the authors have retracted "Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis" Read the Retraction notice and statement from The Lancet hubs.ly/H0r7gh50
RCT with oral ADT. Positive primary end point; sustained testosterone suppression to castrate levels through 48w. Less cardiovascular events (HR 0.46; 95% CI, 0.24 to 0.88). Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. Shore et al
Debbie Robbrecht retweeted
Geriatrician-led CGA + intervention integraded with usual oncological care leads to better quality of life, less unplanned hospital admissions and less treatment discontinuation in older patient receiving #chemotherapy. Nice work from @KhengSoo1 #VirtualASCO #ASCO20 #GeriONC
Impact of Progression at Baseline and On-Treatment Progression Events in Three Large Prostate Cancer Trials - Beyond the Abstract urotoday.com/recent-abstract…
Debbie Robbrecht retweeted
Een thread over de nieuwe mogelijkheid om uitgebreide #DNA diagnostiek te ondergaan bij @ErasmusOncology.
Wij geloven dat #zorgopmaat de toekomst heeft voor patiënten met #kanker
We’re not there yet #patientselection #timing #method. Trédan O, Wang D, Pissaloux P, et al. Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial. Ann Oncol2019; 30(5):757-765.
Debbie Robbrecht retweeted
Now this is exciting. Kras G12c inhibitor. Genuinely seems to be well tolerated and exciting activity especially in #LCSM.
Debbie Robbrecht retweeted
Blijft ‘n fascinerend fenomeen: Sonja Bakker en waarom mensen er steeds weer intuinen. Stevig commentaar in @volkskrant vandaag. Ons boek #VETbelangrijk (co-auteur @BoonMariette) wordt ook besproken, dat volgens de VK ‘wél hout snijdt’ en nog steeds in bestsellerlijsten staat.
median OS 10.1 months (95% CI 8.0–12.3 months) with pembrolizumab vs 7.3 months (95% CI 6.1–8.1 months) with chemotherapy [hazard ratio (HR) 0.70
The >2 year follow-up results of the randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer in @Annals_Oncology show the clinical benefit is durable. ow.ly/yWbV30oMboh
#ASC02019 #Involvement of our Med Oncology Phase 1 Erasmus MC in 2 studies presented at ASCO.
Debbie Robbrecht retweeted
Important reminder: lymph node progression under #immunotherapy may not be tumor progression. Specially relevant in the neoadjuvant setting. Why #pathology matters. #ASCO19 #LCSM – at Chicago, IL
Debbie Robbrecht retweeted
Our department is co-presenting at #ASCO2019. Intruiging data on the importance of #drugdelivery.
@ASCO with two of our posters investigating CPC634 (docetaxel entrapped nanoparticles) #ASCO2019 #ASCO19 #ConquerCancer @ConquerCancerFd @martijn_lolkema
Debbie Robbrecht retweeted
CITN12 1st prospective study of #pembrolizumab in people living with #HIV & #cancer demonstrates safety and activity in several HIV-malignancies ja.ma/2MposfO #ASCO19
Debbie Robbrecht retweeted
Check our our new paper on cost of NGS versus single gene tests=> Economic Impact of Next-Generation Sequencing Versus Single-Gene Testing to Detect Genomic Alterations in Metastatic Non–Small-Cell Lung Cancer Using a Decision Analytic Model #LCSM ascopubs.org/doi/full/10.120…
Debbie Robbrecht retweeted
Androgen deprivation therapy has been considered to be the primary standard of care for those with low volume metastatic prostate cancer.
However, there's now another option. pcf.org/news/a-new-standard-…